Gilead Sciences : View our 2022 Environmental Social Governance Impact Report

2 0 2 2

ENVIRONMENTAL SOCIAL GOVERNANCE IMPACT REPORT

1

CREATING POSSIBLE

1. About Gilead

1. ESG at Gilead

Greg Klak

Vice President, Operations and General Manager, Gilead Alberta

2

INNOVATING FOR

UNMET NEEDS

1. Scientific Innovation

1. Health Equity

1. Access and Affordability

Ana Gonzalez

Director, Medicinal Chemistry

3

EMPOWERING PEOPLE AND COMMUNITIES

58 Engaging and Empowering Employees

60 Inclusion and Diversity

1. Recruitment and Retention

1. Workplace Safety
2. Employee Data

80 The Larger Gilead Community

Roderick Mack

Financial Assistant, Finance

4

SUSTAINING OUR

SHARED PLANET

1. Sustainability Targets

1. Environmental Action

103 Advancing Sustainability

Beyond Gilead

Nicole Kho

Director, Sustainability

C R E A T I N G

I N N O V A T I N G

E M P O W E R I N G

S U S T A I N I N G

R E P O R T I N G

Forward-Looking Statements

Statements included in this 2022 ESG report that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties are identified from time to time in Gilead's reports when filed with the SEC, including annual reports on Form-10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update or supplement any such forward-looking statements other than as required by law. Any forward-looking statements speak only as of the date hereof or as of the dates indicated in the statements.

E N V I R O N M E N T A L S O C I A L G O V E R N A N C E I M P A C T R E P O R T | 2 0 2 2

3

C R E A T I N G

I N N O V A T I N G

E M P O W E R I N G

S U S T A I N I N G

R E P O R T I N G

To All Stakeholders:

Thank you for your interest in Gilead and our ESG commitments. We hope that our inaugural ESG report is an informative resource as part of our ongoing dialogue and engagement with you.

Since its inception in 1987, Gilead has operated with Environmental, Social and Governance principles as an integral part of its business. While the term "ESG" is relatively new, Gilead's business practices over 35 years have always reflected ESG themes in our mission to create a healthier world for all people. We have continued to evolve our approach to ESG over time and today we think about it across three core pillars:

Innovating for Unmet Needs

Empowering People and Communities

Sustaining Our Shared Planet

These pillars, along with a robust governance structure and commitment to the highest standards of ethical conduct, enable Gilead to deliver shareholder value in a sustainable and responsible manner.

E N V I R O N M E N T A L S O C I A L G O V E R N A N C E I M P A C T R E P O R T | 2 0 2 2

4

C R E A T I N G

I N N O V A T I N G

E M P O W E R I N G

S U S T A I N I N G

R E P O R T I N G

In 2022, we successfully delivered against our ESG commitments with examples including:

A newly approved therapy for HIV called Sunlenca. We believe this long-acting therapy, which is currently approved for heavily-treatment experienced individuals living with HIV, has the potential to be the most important tool yet in our goal of helping to end the HIV epidemic.

A new therapeutic option for a type of breast cancer in patients at a very advanced stage of the disease. In addition, new regulatory approvals drove increased demand for our cell therapies, reinforcing our leadership in this transformative type of cancer treatment.

Initiatives that increase patient access and address barriers to health services. For example, more than 20 million people in low-income and lower-middle income countries received HIV treatments based on Gilead's innovation through our voluntary licensing program. Gilead also ranked No. 1 as the top overall philanthropic funder of HIV-related programs by Funders Concerned About AIDS.

Expansion of our unique efforts to increase health equity through robust community partnerships and philanthropy. The Gilead Foundation and Gilead Corporate Giving donated a combined nearly $300 million globally.

Progress against our ambitious climate targets, which include a commitment to a 46% reduction in Scope

1 & 2 GHG emissions by 2030 and to achieve water neutrality in water-stressed regions by 2030. You will see full details of our 2022 progress in the report.

We also continued to prioritize inclusion and diversity. Today more than 60% of our U.S. employees identify as non-white and over 50% identify as female. Our commitment to diversity is long standing and multifaceted. Gilead is taking a strong lead on clinical trial diversity, for example, which was a continued area of focus for the FDA in 2022.

A culture of robust governance and accountability is at the heart of Gilead's ESG progress. Our Board's Nominating and Corporate Governance Committee oversees our ESG commitments and progress, and executive compensation is tied to achieving ambitious ESG goals.

In this inaugural ESG Report we hope to showcase Gilead's leading work across our Environmental, Social and Governance efforts.

All of this work is ultimately in service of the mission that unites all of us at Gilead, which is to create a healthier world for all people.

Daniel O'Day

Chairman and Chief Executive Officer

E N V I R O N M E N T A L S O C I A L G O V E R N A N C E I M P A C T R E P O R T | 2 0 2 2

5